Abstract
Herein we report the design and synthesis of a series of highly selective CCR2 antagonists as 18F‐labeled PET tracers. The derivatives were evaluated extensively for their off‐target profile at 48 different targets. The most potent and selective candidate was applied in vivo in a biodistribution study, demonstrating a promising profile for further preclinical development. This compound represents the first potential nonpeptidic PET tracer for the imaging of CCR2 receptors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have